News
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient
IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the appointment of
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the Japan Patent Office
Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
Valbiotis ernennt Sébastien Bessy, einen internationalen Experten für Consumer Healthcare, zum Chief Operating Marketing and Business Officer
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to
Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
Press release
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a long-term solar energy contract to address the entirety of the Company’s North American electric power requirements with
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association – European Dialysis
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced two e-poster
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the
Valbiotis meldet Veröffentlichung der ersten wissenschaftlichen Beiträge zu TOTUM•63 in drei internationalen Fachzeitschriften — Darlegung des an mehreren Stellen ansetzenden Wirkmechanismus
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
QIAGEN stellt erstes von der FDA zugelassenes gewebebasiertes Begleitdiagnostikum zur Identifizierung von NSCLC-Patienten mit der KRAS-G12C-Mutation bereit und erweitert damit die Möglichkeiten der Präzisionsmedizin im Bereich Lungenkrebs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die Zulassung für das Begleitdiagnostikum therascreen® KRAS RGQ PCR Kit (therascreen KRAS Kit) erweitert wurde. Das